Radioactive gold grain implants in recurrent and locally advanced head-and-neck cancers

Ashamalla, Hani; Rafla, Sameer; Zaki, Bassem I.; Ikoro, Nnaemeka C.; Ross, Pamela

doi:10.1016/s1538-4721(02)00054-5

Cited by 30 publications

(20 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…38 Ashamalla et al reported 94 patients who were treated with gold grain implants; the total radiation dose administered to the patients ranged from 40-120 Gy, with a median of 80 Gy. 39 Complete local tumor control was achieved in 33% cases, palliation was successfully accomplished in 76% cases, cessation of bleeding occurred in 50% cases, pain control was achieved in 88% cases and dysphagia was relieved in 60% cases.…”

Section: Resultsmentioning

confidence: 92%

See 1 more Smart Citation

Percutaneous computed tomography/ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent squamous cell cancers of head and neck

Jiang

Meng²,

Wang³

et al. 2010

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 92%

“…[37][38][39] Martinez et al have reported an overall complication rate of 11% in 48 patients. 40 Goffinet et al reported that approximately half of their patients developed complications.…”

Section: Resultsmentioning

confidence: 99%

Percutaneous computed tomography/ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent squamous cell cancers of head and neck

Jiang

Meng²,

Wang³

et al. 2010

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…For example radioactive gold nanoparticles present attractive prospects in therapy of cancer [1][2][3][10][11][12]. The radioactive properties of Au-198 (β max = 0.96, MeV; t½= 2.7 d) and Au-199 (β max = 0.46 MeV; t ½ = 3.14 d) make them ideal candidates for use in radiotherapeutic applications (Fig.…”

Section: Introductionmentioning

confidence: 99%

“…The radioactive properties of Au-198 (β max = 0.96, MeV; t½= 2.7 d) and Au-199 (β max = 0.46 MeV; t ½ = 3.14 d) make them ideal candidates for use in radiotherapeutic applications (Fig. 6) [1][2][3][10][11][12]. In addition, they both have imagable gamma emissions for dosimetry and pharmacokinetic studies and Au-199 can be made carrierfree by indirect methods.…”

Section: Introductionmentioning

confidence: 99%

Hybrid gold nanoparticles in molecular imaging and radiotherapy

et al. 2006

View full text Add to dashboard Cite

Metallic nanoparticles, because of their size, chemical and physical properties, are particularly attractive as therapeutic probes in treating cancer. Central to any clinical advances in nanoparticulate based therapy will be to produce hybrid nanoparticles that can be targeted to vascular, extracellular or cell surface receptors. Development of hybrid nanoparticles that specifically target cancer vasculature has received considerable attention. Most cancers have leaky vasculature and the defective vascular architecture, created due to the rapid vascularization necessary to serve fast growing cancers, in combination with poor lymphatic drainage allows increased permeation and retention effects. The leaky vasculature, because of higher porosity and permeability, serve as natural high affinity targets to metallic nanoparticles. Another attractive approach toward the application of nanotechnology to nanomedicine is the utility of nanoparticles that display inherent therapeutic properties. For example radioactive gold nanoparticles present attractive prospects in therapy of cancer. The radioactive properties of Au-198 (β max = 0.96 MeV; t ½ = 2.7 d) and Au-199 (β max = 0.46 MeV; t ½ = 3.14 d) make them ideal candidates for use in radiotherapeutic applications. In addition, they both have imageable gamma emissions for dosimetry and pharmacokinetic studies and Au-199 can be made carrier-free by indirect methods. Gold nanoparticles are of interest for treatment of disease as they can deliver agents directly into cells and cellular components with a higher concentration of radioactivity, e.g. higher dose of radioactivity, to cancerous tumor cells.

show abstract

“…[36] 70 İridium 72 Ashamalla ve ark. [37] 37 Altın 52 AKK 33 Tam yanıt 10 10 SHK Kısmi yanıt 18 Puthawala ve ark. [38] 220 (iridium) İridium 10 SHK 60 69 Kolotas ve ark.…”

Section: B-argon Plazma Koagülasyon (Apk)unclassified

The final resort treatment options of recurrent head and neck cancer

Karakullukçu¹

2017

Kulak Burun Bogaz Ihtis Derg

View full text Add to dashboard Cite

ÖZBaş boyun kanserlerinde tedaviye rağmen nüks oranı %30 ila %50 arasında değişmektedir. Nüks görülen hastaların ise %50'den fazlası, kurtarma tedavisine rağmen kaybedilmektedir. Klinik uygulamada tedavi genellikle cerrahi, radyoterapi ve kemoterapiyi kapsamaktadır. Ancak nüks görülen hastalarda bu yöntemler çoğu zaman istenen sonucu verememektedir. Bu derlemede, nüks baş boyun kanserlerinin tedavisinde klinik uygulamada kullanılan yöntemler dışında kalan son yöntemler ve klinik sonuçları sunuldu.Anahtar Sözcükler: Baş boyun kanseri; nüks; tedavi. ABSTRACTDespite treatment, the recurrence rate of head and neck cancers varies between 30 and 50%. More than 50% of the patients with recurrence die, despite rescue therapy. In clinical practice, treatment usually encompasses surgery, radiotherapy, and chemotherapy. However, these methods do not often yield desirable outcomes in patients with recurrence. In this review, we present the final resort methods, except conventional methods used for the treatment of recurrent head and neck cancers in the clinical practice, and their clinical outcomes.Keywords: Head and neck cancer; recurrent; treatment.Baş boyun kanserleri tüm malignitelerin %10'unu oluşturur. Bunların %90'ını ise skuamöz hücreli karsinom oluşturur.[1] Baş boyun kanserlerinin tedavisinde cerrahi sonrası radyoterapi veya kemoradyoterapide başarısızlık oranı %30-50 arasında değişmektedir. Nüks baş ve boyun kanseri olan hastaların %50'den fazlası kurtarma tedavisine rağmen kaybedilmektedir. Cerrahi etkili bir tedavi seçeneğidir. Ancak sık-lıkla nüks tümörler, kafa tabanı, arteriyel damarlar veya çene gibi kritik yapılara infiltrasyonu nedeniyle rezektabl değildir. [2] Nüks baş boyun tümörlerinin cerrahi tedavisinde en geniş metaanaliz çalışmalarından biri olan Goodwin'in çalışmasında 32 yayın taranmış ve 1633 nüks baş boyun kanser hastası değerlen-dirilmiştir. Hastaların %99'unun daha önce radyasyon tedavisi aldığı belirtilmiştir. Bölgelerine göre beş yıllık sağkalım oranı larenks tümörün-de %47.5 (n=293), oral kavite tümöründe %43.4 (n=116), farenks tümöründe %26 (n=266) olarak bulunmuştur. Bölgelerin tümüne baktığımızda beş yıllık sağkalım oranı %39.4 (n=1080) olarak bulunmuştur.[3]

show abstract

Radioactive gold grain implants in recurrent and locally advanced head-and-neck cancers

Cited by 30 publications

References 18 publications

Percutaneous computed tomography/ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent squamous cell cancers of head and neck

Percutaneous computed tomography/ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent squamous cell cancers of head and neck

Hybrid gold nanoparticles in molecular imaging and radiotherapy

The final resort treatment options of recurrent head and neck cancer

Contact Info

Product

Resources

About